30 September 2015 - CADTH has received notice of a pending submission from AbbVie for adalimumab (Humira) for patients with hidradenitis suppurativa. For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website.

For more details, go to: https://www.cadth.ca/adalimumab-humira